Severe COPD Clinical Trial
Official title:
Daxas in COPD Therapy
Daxas (roflumilast) is the first oral anti-inflammatory phosphodiesterase inhibitor (PDE-4)
for patients with severe chronic obstructive pulmonary disease (COPD) experiencing chronic
cough and sputum and with a history of exacerbations as add-on to bronchodilator treatment.
With its mode of action Daxas can reduce exacerbations rates and improve lung function
parameters which may result in a better health-related quality of life and an improved
long-term management of COPD.
The aim of this non-interventional study is to evaluate data on quality of life in COPD
patients in Germany in a real life medical setting. Evaluation is based on two COPD specific
questionnaires to assess the patient`s health status over six months. During the study,
socio-demographic data and cost-of-illness data will be recorded. Daxas (tablet) will be
administered once daily. The study will provide further data on the safety and tolerability
of Daxas.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03915743 -
Advance Care Planning Individualised Approach and Research Projec
|
N/A | |
| Completed |
NCT04023409 -
The Identification of Phenotypes in Patients With Severe Chronic Obstructive Pulmonary Disease (Groningen Severe COPD Cohort)
|